Our CRISPR genome-wide loss-of-function screen was performed in four nonisogenic colorectal and pancreatic cancer cell lines, two SMAD4-negative and two SMAD4-positive cell lines. This evidence concerns the gene SMAD4 and pancreatic neoplasm.